新诺威：控股子公司SYS6036注射液获得药物临床试验批准通知书

Core Viewpoint - The company announced that its subsidiary, Jushi Biotech, has received approval from the National Medical Products Administration for the clinical trial of SYS6036 injection, a humanized monoclonal antibody drug for tumor immunotherapy [1] Company Summary - SYS6036 injection is expected to be applicable for the treatment of various tumors [1] - The approval allows the company to conduct clinical trials as a biosimilar drug, but the drug must still undergo clinical trials and receive further regulatory approval before it can be marketed and sold [1] - The development of the drug involves high investment, high risk, and long cycles, indicating potential challenges ahead [1] - In the short term, the approval is not expected to have a significant impact on the performance of Jushi Biotech or the company as a whole [1]